NCT07151508View on ClinicalTrials.gov

Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

December 25, 2024

Study Completion Date

January 10, 2025

Conditions
Neterton Syndrome
Interventions
DEVICE

Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age

"Secukinumab was administered in a weight-adapted dosing regimen equivalent to that used in clinical trials for psoriasis: 75 mg for less than 25 kg,150 mg for 25 to 50 kg, and 300 mg for greater than 50 kg at baseline and weeks1,2,3, and 4 and monthly there after.~Dupilumab was administered at a dose dependent on the patient's weight and age in accordance with the instructions."

Trial Locations (1)

Unknown

Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow

All Listed Sponsors
lead

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

OTHER

NCT07151508 - Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab | Biotech Hunter | Biotech Hunter